Disease-Modifying Antirheumatic Drugs (DMARDs) play a vital role in the management of Rheumatoid Arthritis (RA). This update aims at focusing some
important and novel aspects of biological DMARDs. Recent advances in biological therapy have opened a new window of opportunity for this potentially crippling disorder particularly patients refractory to conventional DMARDs.